Results 21 to 30 of about 7,224 (167)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV

Journal of Virus Eradication, 2021
This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3​TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen.
Laura Waters, Viraj Mehta, Jaideep Gogtay, Marta Boffito   +3 more
doaj   +1 more source

Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday

Molecules, 2021
Nucleoside and nucleotide analogues are essential antivirals in the treatment of infectious diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), varicella-zoster virus (VZV ...
Guangdi Li, Tingting Yue, Pan Zhang, Weijie Gu, Ling-Jie Gao, Li Tan   +5 more
doaj   +1 more source

Acquired Fanconi Syndrome from Tenofovir Treatment in a Patient with Hepatitis B

Case Reports in Hepatology, 2023
Fanconi syndrome is a rare disease of generalized proximal tubule dysfunction which can be acquired secondary to certain medications, including tenofovir, a commonly used hepatitis B treatment.
Shirley X. Jiang, John Duncan, Hin Hin Ko   +2 more
doaj   +1 more source

The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation

Терапевтический архив, 2021
Aim. To analyze the features of drugs provision for special groups of treatment-nave HIV-infected patients initiating antiretroviral treatment with fixed dose combination (FDC) for once-daily single-tablet regimen, in Russian healthcare setting ...
Elena A. Pyadushkina, Elena V. Derkach
doaj   +1 more source

A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia

AIDS Research and Therapy, 2023
Background Bictegravir (BIC) co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) is approved by Federal Food and Drug Administration in 2018 for both treatment-naïve and experienced persons living with HIV (PLWH).
Kanak Parmar, Poemlarp Mekraksakit, Kenneth Nugent, Jacob Nichols   +3 more
doaj   +1 more source

Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV

Viruses, 2023
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens.
María F. Rombini, Diego Cecchini, Sofía Diana Menendez, Liliana Calanni, Rosana Cuini, Elena Obieta, María M. Greco, Fabricio Morales, Laura Morganti, Claudia Migazzi, Yasmin El Kozah, Pablo Parenti, Isabel Cassetti, on behalf of the COVIDARE Study Team   +13 more
doaj   +1 more source

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form

Journal of Taibah University for Science, 2019
A new simple, accurate, precise RP-HPLC [reverse phase high performance liquid chromatography] method was developed for the simultaneous estimation of the Emtricitabine, Bictegravir and Tenofovir alafenamide in pharmaceutical dosage form.
Tej Kumar Kokkirala, Duvvuri Suryakala
doaj   +1 more source

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction

BMC Infectious Diseases, 2018
Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee, Joshua P. Havens, Harlan R. Sayles, Jennifer L. O’Neill, Anthony T. Podany, Susan Swindells, Kimberly K. Scarsi, Sara H. Bares   +7 more
doaj   +1 more source

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Microbiology Spectrum, 2023
Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited.
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung   +15 more
doaj   +1 more source

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide

Clinical Case Reports, 2023
Key Clinical Message At 22 weeks post‐transplantation for HBV‐related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID‐19 (ANC 0.4 × 109/L). Covid resolution and all “conventional” modifications were ineffective.
I. Vern Lim, Nurgül Özgür Yurttaş, Mesut Ayer, Şule Poturoğlu, Erdem Kınacı, İlgin Özden   +5 more
doaj   +1 more source